Real world performance of inactivated SARS-CoV-2 vaccine (CoronaVac) against infection, hospitalization and death due to COVID-19 in adult population in Indonesia

  1. Anton Suryatma
  2. Raras Anasi
  3. Miko Hananto
  4. Asep Hermawan
  5. Ririn Ramadhany
  6. Irene Lorinda Indalao
  7. Agustiningsih Agustiningsih
  8. Ely Hujjatul Fikriyah
  9. Kristina Lumban Tobing
  10. Teti Tejayanti
  11. Rustika Rustika
  12. Pandji Wibawa Dhewantara
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Background

Inactivated SARS-CoV-2 vaccine has been included in the national COVID-19 vaccination program in Indonesia since January 2021. The study aims to assess the impacts of inactivated COVID-19 vaccine on infection, hospitalization, and death among adult population aged ≥18 years in Bali, Indonesia.

Methods

Test-negative, case control study was conducted by linking SARS-CoV-2 laboratory records, vaccination, and health administrative data for the period of January 13 to June 30, 2021. Case-subjects were defined as individuals who had a positive RT-PCR test for SARS-CoV-2 during the period; they were matched with controls (tested negative) (1:1) based on age, sex, district of residence, and week of testing. We estimated the odds of vaccination in PCR confirmed, hospitalization and death due to COVID-19, accounting for the presence of comorbidities and prior infection. Vaccine effectiveness was estimated as (1-odds ratio) x 100%.

Results

Total 109,050 RT-PCR test results were retrieved during the January 13 to June 30, 2021. Of these, 14,168 subjects were eligible for inclusion in the study. Total 5518 matched case-control pairs were analyzed. Adjusted vaccine effectiveness (VE) against laboratory-confirmed SARS-CoV-2 infection was 14.5% (95% confidence interval -11 to 34.2) at 0-13 days after the first dose; 66.7% (95% CI: 58.1-73.5) at ≥14 days after the second dose. The adjusted effectiveness against hospitalization and COVID-19-associated death was 71.1% (95% CI: 62.9-77.6) and 87.4% (95% CI: 65.1-95.4%) at ≥14 days after receiving the second dose, respectively.

Conclusions

Two-dose of inactivated CoronaVac vaccine showed high effectiveness against laboratory confirmed COVID-19 infection, hospitalization, and death associated with COVID-19 among adults aged ≥18 years.

Related articles

Related articles are currently not available for this article.